ERBB2 and breast carcinoma: Additionally, epigenetic modulators such as EZH2 and HDAC inhibitors can reverse the silencing of the IFI16-STING-CXCL10/11 signaling pathway in HER2+ breast cancer, priming tumors for trastuzumab response and creating novel combinatorial therapeutic opportunities for clinical translation (89).